4D Molecular Therapeutics (FDMT) Change in Accured Expenses (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Change in Accured Expenses data on file, last reported at -$4.1 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 78.33% year-over-year to -$4.1 million in Q1 2026; TTM through Mar 2026 was $6.3 million, a 3.94% decrease from a year earlier, with the FY2025 full-year figure at $8.2 million, up 24.95% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.1 million, down from $2.4 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for FDMT reached as high as $8.1 million in Q3 2024 and fell as low as -$4.1 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $965235.3 across 5 years, with a median of $1.2 million in 2023.
• Across the five-year window, Change in Accured Expenses jumped 240.75% in 2022 and plunged 218.48% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.8 million in 2022, then increased by 9.54% to $2.0 million in 2023, then plunged by 218.48% to -$2.4 million in 2024, then surged by 200.25% to $2.4 million in 2025, then slumped by 273.82% to -$4.1 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$4.1 million in Q1 2026, $2.4 million in Q4 2025, and $5.0 million in Q3 2025.